Compare TG Therapeutics Inc (TGTX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 2.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| TGTX | USIG | |
|---|---|---|
Market Cap | $8.16B | $17.53B |
Volume | 1,735,121 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $52.69 |
52-Week Low | $26.94 | $48.54 |
Typical Hold Time | 16 Days | 44 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
USIG trades at $48.79 with a slight 0.23% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital and Bank of New York Mellon increasing positions, indicating institutional confidence despite the bearish technical outlook.
The outlook remains cautious due to bearish technical signals and limited fundamental data availability. Investment opportunities hinge on institutional accumulation and dividend consistency, while risks include technical weakness and potential market volatility. Investors should monitor upcoming financial disclosures for clearer fundamental direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
